



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mpi (h): 293T Lysate: sc-115944

BACKGROUND

Mpi (mannose phosphate isomerase), also known as PMI (phosphomannose isomerase) or PMI1, is a 423 amino acid zinc metalloenzyme belonging to the mannose-6-phosphate isomerase type 1 family, and is expressed in all tissues, more abundantly in heart, brain and skeletal muscle. A steady supply of D-mannose derivatives, which are required for most glycosylation reactions, is maintained by Mpi. Localized to the cytoplasm, Mpi utilizes zinc as a cofactor and catalyzes the interconversion of fructose-6-phosphate and mannose-6-phosphate. Mutations in the gene encoding Mpi lead to congenital disorder of glycosylation type 1B (CDG1B), also designated carbohydrate-deficient glycoprotein syndrome type 1b (CDGS1B), which is characterized by protein-losing enteropathy. Congenital disorders of glycosylation are metabolic deficiencies in glycoprotein biosynthesis that usually results in severe mental and psychomotor retardation.

REFERENCES

1. Proudfoot, A.E., Goffin, L., Payton, M.A., Wells, T.N. and Bernard, A.R. 1996. *In vivo* and *in vitro* folding of a recombinant metalloenzyme, phosphomannose isomerase. *Biochem. J.* 318: 437-442.
2. Jaeken, J., Matthijs, G., Saudubray, J.M., Dionisi-Vici, C., Bertini, E., de Lonlay, P., Henri, H., Carchon, H., Schollen, E. and Van Schaftingen, E. 1998. Phosphomannose isomerase deficiency: a carbohydrate-deficient glycoprotein syndrome with hepatic-intestinal presentation. *Am. J. Hum. Genet.* 62: 1535-1539.
3. Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H.G., Zimmer, K.P., Wu, R., Harms, E., Reiter, K., von Figura, K., Freeze, H.H., Harms, H.K. and Marquardt, T. 1998. Carbohydrate-deficient glycoprotein syndrome type 1b. Phosphomannose isomerase deficiency and mannose therapy. *J. Clin. Invest.* 101: 1414-1420.
4. Schollen, E., Dorland, L., de Koning, T.J., Van Diggelen, O.P., Huijman, J.G., Marquardt, T., Babovic-Vuksanovic, D., Patterson, M., Imtiaz, F., Winchester, B., Adamowicz, M., Pronicka, E., Freeze, H. and Matthijs, G. 2000. Genomic organization of the human phosphomannose isomerase (MPI) gene and mutation analysis in patients with congenital disorders of glycosylation type 1b (CDG-1b). *Hum. Mutat.* 16: 247-252.
5. de Lonlay, P., Seta, N., Barrot, S., Chabrol, B., Drouin, V., Gabriel, B.M., Journal, H., Kretz, M., Laurent, J., Le Merrer, M., Leroy, A., Pedespan, D., Sarda, P., Villeneuve, N., Schmitz, J., van Schaftingen, E., Matthijs, G., Jaeken, J., Korner, C., Munnich, A., Saudubray, J.M. and Cormier-Daire, V. 2001. A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. *J. Med. Genet.* 38: 14-19.
6. Schollen, E., Martens, K., Geuzens, E. and Matthijs, G. 2002. DHPLC analysis as a platform for molecular diagnosis of congenital disorders of glycosylation (CDG). *Eur. J. Hum. Genet.* 10: 643-648.
7. Vuillaumier-Barrot, S., Le Bizet, C., de Lonlay, P., Barnier, A., Mitchell, G., Pelletier, V., Prevost, C., Saudubray, J.M., Durand, G. and Seta, N. 2002. Protein losing enteropathy-hepatic fibrosis syndrome in Saguenay-Lac St-Jean, Quebec is a congenital disorder of glycosylation type 1b. *J. Med. Genet.* 39: 849-851.

CHROMOSOMAL LOCATION

Genetic locus: MPI (human) mapping to 15q24.1.

PRODUCT

Mpi (h): 293T Lysate represents a lysate of human Mpi transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

Mpi (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive Mpi antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

Mpi (E-4): sc-393477 is recommended as a positive control antibody for Western Blot analysis of enhanced human Mpi expression in Mpi transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



Mpi (E-4): sc-393477. Western blot analysis of Mpi expression in non-transfected: sc-117752 (A) and human Mpi transfected: sc-115944 (B) 293T whole cell lysates.



Mpi (B-2): sc-393484. Western blot analysis of Mpi expression in non-transfected: sc-117752 (A) and human Mpi transfected: sc-115944 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.